Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Serum Institute of India Private Limited is a leading biopharmaceutical company that specializes in the development and production of vaccines and immunobiologicals. It offers a diverse range of vaccines targeting infectious diseases, including polio, measles, and hepatitis, and serves the global market by supplying to over 170 countries, addressing critical health needs.
Serum Institute Of India Private Limited, is an unlisted private company incorporated on 22 May, 1984. It is classified as a private limited company and is located in , Maharashtra. It's authorized share capital is INR 55.00 cr and the total paid-up capital is INR 4.82 cr.
Read more
** All rupee values in INR crores. Based on March 2025 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
| State | Type | Address |
|---|
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Whole-time Director | Adar Cyrus Poonawalla
Shareholder
|
00044815 | 18 years |
| Managing Director | Cyrus Soli Poonawalla
Shareholder
|
00044650 | 19 years |
| Whole-time Director | Sunil Gairola | 08893242 | 4 years |
| Whole-time Director | Umesh Sharadrao Shaligram | 00212458 | 4 years |
| Whole-time Director | Satish Ramchandra Mundra | 00416654 | 16 years |
| Whole-time Director | Natasha Adar Poonawalla | 01264082 | 10 years |
| Whole-time Director | Prasad Suryakant Kulkarni | 08991838 | 4 years |
| Director | Behroze Zavareh Poonawalla | 00044877 | 40 years |
| Director | Zavareh Soli Poonawalla
Shareholder
|
00044760 | 42 years |
| Whole-time Director | Kedar Shashikant Gokhale | 08788551 | 4 years |
| Whole-Time Director | Parag Rajendra Deshmukh | 03377341 | 1 years |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales | 7,201.0 | 25,645.0 | 10,190.0 | 9,549.0 | 9,715.0 |
| Operating profit | 4,247.0 | 17,445.0 | 5,630.0 | 4,516.0 | 4,242.0 |
| Net profit | 3,891.0 | 11,116.0 | 4,187.0 | 4,278.0 | 4,630.0 |
| Gross margin | 94.4 | 84.9 | 88.4 | 86.8 | 86.6 |
| Operating margin | 59.0 | 68.0 | 55.2 | 47.3 | 43.7 |
| Net margin | 46.7 | 41.6 | 39.0 | 38.6 | 42.7 |
| Networth | 21,839.0 | 32,933.0 | 36,902.0 | 41,187.0 | 45,741.0 |
| Borrowings | 196.0 | 191.0 | 57.0 | 302.0 | 382.0 |
| Assets | 26,446.0 | 37,133.0 | 40,049.0 | 44,654.0 | 48,678.0 |
| Debt to equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current ratio | 1.9 | 2.0 | 3.7 | 4.0 | 4.2 |
| ROE | 17.8 | 33.8 | 11.3 | 10.4 | 10.1 |
| Days payable | 354.0 | 56.0 | 167.0 | 235.0 | 209.0 |
| WC days | 188.0 | 51.0 | 233.0 | 314.0 | 278.0 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
| Reserves | 21,834.2 | 32,928.2 | 36,897.2 | 41,182.2 | 45,736.2 |
| Borrowings + | 196.0 | 191.0 | 57.0 | 302.0 | 382.0 |
| Long term borrowings | - | - | - | - | - |
| Short term borrowings | 196.0 | 191.0 | 57.0 | 302.0 | 382.0 |
| Trade payables + | 391.0 | 591.0 | 540.0 | 812.0 | 746.0 |
| Days payable | 354.0 | 56.0 | 167.0 | 235.0 | 209.0 |
| Other liabilities + | 4,411.0 | 4,009.0 | 3,090.0 | 3,165.0 | 2,555.0 |
| Other non-current liabilities | 456.0 | 535.0 | 714.0 | 691.0 | 662.0 |
| Other current liabilities | 3,564.0 | 2,883.0 | 1,836.0 | 1,662.0 | 1,147.0 |
| Total liabilities | 26,446.0 | 37,133.0 | 40,049.0 | 44,654.0 | 48,678.0 |
| Fixed Assets + | 4,730.0 | 4,754.0 | 6,114.0 | 9,029.0 | 10,472.0 |
| Tangible assets | 1,991.0 | 2,279.0 | 2,174.0 | 1,967.0 | 2,309.0 |
| CWIP | 2,539.0 | 2,348.0 | 3,853.0 | 6,869.0 | 7,339.0 |
| Intangible assets | 200.0 | 127.0 | 87.0 | 193.0 | 824.0 |
| LT loans and advances | 226.0 | 68.0 | 331.0 | 211.0 | 34.0 |
| Other non-current assets | 13,627.0 | 25,054.0 | 24,679.0 | 24,421.0 | 28,502.0 |
| Current assets + | 7,863.0 | 7,257.0 | 8,925.0 | 10,993.0 | 9,670.0 |
| Inventories | 2,855.0 | 2,618.0 | 3,735.0 | 4,505.0 | 5,309.0 |
| Trade receivables | 2,205.0 | 2,725.0 | 3,079.0 | 2,124.0 | 1,570.0 |
| Cash and cash equivalents | 1,757.0 | 953.0 | 733.0 | 1,072.0 | 1,740.0 |
| ST loans and advances | 58.0 | - | 328.0 | 178.0 | 183.0 |
| Other current assets | 988.0 | 961.0 | 1,050.0 | 3,114.0 | 868.0 |
| Total assets | 26,446.0 | 37,133.0 | 40,049.0 | 44,654.0 | 48,678.0 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales + | 7,201.0 | 25,645.0 | 10,190.0 | 9,549.0 | 9,715.0 |
| Sales growth % | 32.23 | 256.13 | -60.27 | -6.29 | 1.74 |
| Expenses + | 3,427.0 | 9,779.0 | 5,404.0 | 5,658.0 | 6,190.0 |
| Cost of goods | 403.0 | 3,878.0 | 1,181.0 | 1,261.0 | 1,302.0 |
| Employee cost | 1,350.0 | 1,917.0 | 1,368.0 | 1,458.0 | 1,504.0 |
| Other costs | 1,201.0 | 2,405.0 | 2,011.0 | 2,314.0 | 2,667.0 |
| Operating profit + | 4,247.0 | 17,445.0 | 5,630.0 | 4,516.0 | 4,242.0 |
| Operating margin % | 59.0 | 68.0 | 55.2 | 47.3 | 43.7 |
| Other income | 1,134.0 | 1,073.0 | 543.0 | 1,527.0 | 1,139.0 |
| Interest | 43.0 | 70.0 | 64.0 | 65.0 | 84.0 |
| Depreciation | 430.0 | 1,509.0 | 780.0 | 560.0 | 633.0 |
| Exceptional items | - | - | - | - | - |
| Profit before tax | 4,908.0 | 16,939.0 | 5,329.0 | 5,418.0 | 4,664.0 |
| Tax | 1,017.0 | 5,823.0 | 1,142.0 | 1,140.0 | 34.0 |
| Profit - disc. ops | - | - | - | - | - |
| Net profit | 3,891.0 | 11,116.0 | 4,187.0 | 4,278.0 | 4,630.0 |
| Net margin % | 46.7 | 41.6 | 39.0 | 38.6 | 42.7 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Debt/Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Debt/Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Assets/Equity | 1.2 | 1.1 | 1.1 | 1.1 | 1.1 |
| Liquidity + | |||||
| Current Ratio | 1.9 | 2.0 | 3.7 | 4.0 | 4.2 |
| Quick Ratio | 1.2 | 1.3 | 2.1 | 2.3 | 1.9 |
| Interest Coverage | 98.8 | 249.2 | 88.0 | 69.5 | 50.5 |
| Performance | |||||
| Gross Margin | 94.4 | 84.9 | 88.4 | 86.8 | 86.6 |
| Operating Margin | 59.0 | 68.0 | 55.2 | 47.3 | 43.7 |
| Net Margin | 46.7 | 41.6 | 39.0 | 38.6 | 42.7 |
| Return + | |||||
| Return on Equity | 17.8 | 33.8 | 11.3 | 10.4 | 10.1 |
| Pre-tax ROCE | 45.2 | 190.9 | 38.5 | 22.9 | 20.2 |
| Return on Assets | 14.7 | 29.9 | 10.4 | 9.6 | 9.5 |
| Pre-tax ROIC | 17.5 | 48.4 | 13.1 | 9.6 | 7.9 |
| Efficiency + | |||||
| Days Payable | 354.0 | 56.0 | 167.0 | 235.0 | 209.0 |
| Days Inventory | 2,586.0 | 246.0 | 1,154.0 | 1,304.0 | 1,488.0 |
| Days Receivable | 112.0 | 39.0 | 110.0 | 81.0 | 59.0 |
| Fixed Asset Turnover | 1.5 | 5.4 | 1.7 | 1.1 | 0.9 |
| Total Asset Turnover | 0.3 | 0.7 | 0.2 | 0.2 | 0.2 |
| Working Capital | |||||
| Cash Conversion Cycle | 2,344.0 | 229.0 | 1,097.0 | 1,150.0 | 1,338.0 |
| Working Capital Days | 188.0 | 51.0 | 233.0 | 314.0 | 278.0 |
As per information available, the company has no registered charges.
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| SERUM INTERNATIONAL B.V. | Netherlands | - | - |
| Bilthoven Biologicals B.V. | Netherlands | - | - |
| SERUM INSTITUTE INC | United States | - | - |
| Serum Life Science Europe Gmbh | Germany | - | - |
| SEZ BIOTECH SERVICES PRIVATE LIMITED | 2006 | ₹ 1,300.4 Cr | |
| POONAWALLA AVIATION PRIVATE LIMITED | Maharashtra | 2005 | ₹ 2,105.2 Cr |
| Serum Life Sciences B.V | Netherlands | - | - |
| Serum AMR Products B.V. | Netherlands | - | - |
| SERUM INSTITUTE LIFE SCIENCES PRIVATE LIMITED | Maharashtra | 2020 | ₹ 636.6 Cr |
| Serum Life Sciences Ltd | United Kingdom | - | - |
| COVIDSHIELD TECHNOLOGIES PRIVATE LIMITED | Maharashtra | 2019 | ₹ 7.5 Cr |
| SERUM INSTITUTE VACCINES PRIVATE LIMITED | Maharashtra | 2021 | ₹ 113.3 Cr |
| SERUM LIFECARE FOUNDATION | Maharashtra | 2023 | ₹ 0.0 |
| Serum Global FZCO | United Arab Emirates | - | - |
| Serum Middle East Holdings FZCO | United Arab Emirates | - | - |
| Diamond Worldwide Finance Ltd | Virgin Islands, British | - | - |
Read more
The incorporation date of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is 22 May, 1984
The authorized share capital of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is INR ₹ 55.0 Cr.
The paid-up capital of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is INR ₹ 4.8 Cr.
The registered address of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is 212/2 OFF SOLI POONAWALLA ROAD, HADAPSAR, Pune, PUNE, Maharashtra, India, 411028 - 411028
The CIN number of SERUM INSTITUTE OF INDIA PRIVATE LIMITED is U80903PN1984PTC032945.